Quick Facts

• Relief of Heartburn: May assist in addressing discomfort associated with acid reflux.
• Management of Acid Indigestion: Contributes to the reduction of symptoms related to excess stomach acid.
• Relief of Upset Stomach: Used to ease symptoms of stomach distress linked to hyperacidity.

---

What Gaviscon Forte is Used For

Gaviscon Forte is a commonly available over-the-counter medicine utilized for the symptomatic relief of conditions caused by stomach acid moving back into the esophagus. The primary therapeutic focus is on the management of heartburn and acid indigestion, which are key symptoms of gastroesophageal reflux (GER) and gastroesophageal reflux disease (GERD).

This medication works to help address discomfort and burning sensations in the chest and throat, as well as the feeling of a sour stomach or upset stomach that is associated with these reflux episodes. For individuals who experience symptoms following meals or at night, Gaviscon Forte provides a therapeutic option to mitigate these episodes.

It is indicated for use in addressing symptoms of acid reflux and related issues, which may include the sensation of acid regurgitation.

---

The eligibility for using Gaviscon Forte (Sodium Alginate, Potassium Bicarbonate, Calcium Carbonate oral suspension) is determined by regulatory agencies based on age, hypersensitivity, and underlying medical conditions.

---

Eligibility Scope

Populations for whom use is contraindicated:

• Patients with known or suspected hypersensitivity to the active substances (Sodium Alginate, Potassium Bicarbonate, Calcium Carbonate) or any other component in the medicine, such as the parabens (e.g., methyl parahydroxybenzoate).

Age-Related Eligibility Rules:

• Adults and adolescents (12 years and over): Use is generally permitted under standard labeled conditions.
• Children under 12 years: Use in this age group is not generally recommended and must only be initiated on medical advice.
• Older Adults (Geriatric): No specific dose modification is required for this population.

Conditional Use and Caution:

• Patients with certain renal impairment (reduced kidney function) and those on a strictly low-salt (low sodium) diet must exercise caution due to the product's high sodium content.
• Caution is also mandated for individuals with a history of hypercalcaemia (high calcium levels), nephrocalcinosis, or recurrent calcium-containing kidney stones due to the presence of Calcium Carbonate.

Pregnancy and Lactation Eligibility Status:

• Pregnancy: Use is generally permitted if clinically needed, as post-marketing data indicate no known risks of toxicity.
• Lactation: Use is permitted, as the active ingredients are not known to affect breastfed infants.

Interactions with other medicines and products

The official regulatory profile for Gaviscon Forte documents an interaction pattern where co-administration interferes with the absorption of certain other oral medicinal products. This is officially classified as an exposure-modifying interaction that leads to a reduced oral exposure and decreased systemic bioavailability of the partner medicine.

Medicines Requiring Timing Separation

The established regulatory requirement to manage this interaction is the enforcement of a mandatory time interval between doses. A separation of at least two hours must be observed between the consumption of Gaviscon Forte and the following medicinal products to ensure their therapeutic efficacy:

• Antibiotics: Including Tetracyclines and Fluoroquinolones.
• Thyroid Hormones: Levothyroxine.
• Cardiac/Other Agents: Digoxine, Iron salts, Ketoconazole, Penicillamine, Neuroleptics, Glucocorticoids, and certain Beta-blockers.

Official Regulatory Constraints

Hypersensitivity to any of the product’s active substances or excipients is documented as a use restriction. Population-specific cautions are also noted; individuals with severe renal dysfunction must be monitored closely due to the potential for accumulation of the product’s potassium and calcium components. No specific CYP-enzyme or other metabolic interactions are officially specified in regulatory labeling. The co-administration of herbal remedies or supplements is not associated with officially documented problems.

Physicochemical Transformation and Raft Formation

The mechanism begins with a physical precipitation reaction: the key structural ingredient, Sodium Alginate, transforms into an insoluble, cohesive alginic acid gel upon contact with the low pH environment of the stomach. This chemical change is non-systemic, targeting the gastric fluid rather than biological receptors. The reaction creates the physical matrix of the barrier, which forms the basis of the drug's physiological action.

---

Synergistic Buoyancy and Structural Stability

The functional capability of the barrier relies on direct synergistic chemical reactions between all three active ingredients. Potassium Bicarbonate reacts to produce CO2 gas that is trapped within the gel, providing the necessary buoyancy for the raft to float. Simultaneously, Calcium Carbonate supplies Ca^2+ ions that chemically cross-link the alginate polymers, increasing the barrier's structural strength and viscosity.

---

Mechanical Barrier and Physiological Separation

The combined physicochemical actions result in a buoyant, high-viscosity barrier that floats atop the gastric contents, functioning as a mechanical boundary at the gastroesophageal junction. This physical obstruction is the basis of the drug's physiological effect, separating the underlying gastric contents from the esophageal mucosa. The mechanism is strictly pH-dependent, requiring adequate gastric acid to initiate precipitation and CO2 generation.

The administration of Gaviscon Forte Oral Suspension is by the oral route. Proper use involves following specific parameters regarding dose, frequency, and timing.

Standard Adult Administration

The standard adult dose typically ranges from 10 mL to 20 mL per single dose of the suspension. This medicine is taken up to four times per day (QDS). The use pattern is structured around mealtimes and sleep, with administration generally occurring after meals and at bedtime. The maximum daily dose is constrained to 80 mL over any 24-hour period.

Procedural Requirements and Constraints

Prior to measuring a dose, the liquid suspension must be shaken well to ensure that the active components are uniformly distributed. A critical procedural constraint involves co-administering Gaviscon Forte with other oral medicines; a 2-hour interval is required between the two to prevent potential interference with the absorption of the secondary medication.

The instructions specify that the medicine is for short-term use. If symptoms persist after seven days of continuous use, a medical review of the condition is required.

Use in Specific Populations

Older adults do not require a specific dose adjustment; the standard adult regimen is applicable. For children under 12 years of age, use is restricted to only on medical advice.

Research Evidence / Overview of Studies for Gaviscon Forte

Gastroesophageal Reflux Disease (GERD) and Heartburn

Research has consistently explored the effects of products like Gaviscon Forte on people experiencing the symptoms of Gastroesophageal Reflux Disease (GERD), often referred to as heartburn. The studies conducted for this use are typically Randomized Controlled Trials (RCTs). In these types of trials, volunteers are randomly assigned to receive either the substance being tested or a placebo (an inactive substance) or another treatment, which helps researchers compare the effects accurately.

The main findings from these studies suggest that studies exploring Gaviscon Forte reported observations of symptom change in GERD, particularly for heartburn and acid regurgitation (stomach acid coming back up the throat). When compared to a placebo, findings included observations of a decrease in the frequency and severity of these symptoms. Some studies have also compared this treatment to other types of acid-reducing medicines. These comparisons suggest that some studies reported a quicker start to symptom change compared to other treatments for immediate symptoms of heartburn.

Despite consistent findings on symptom change, some aspects remain uncertain or have been less studied. While the treatment is often explored for its effect on symptoms, less research is available on its long-term impact on the deeper damage sometimes caused by GERD to the lining of the esophagus. Also, research might be limited regarding its use for every single sub-type or severity level of GERD. The majority of studies focus on typical, uncomplicated heartburn and acid regurgitation.

---

Indigestion (Dyspepsia)

Research has also investigated the effects of this treatment on symptoms of indigestion, also known as dyspepsia. Indigestion is a general term for discomfort or pain in the upper abdomen, often including feelings of fullness, bloating, or nausea. Similar to GERD research, studies for indigestion frequently involve Randomized Controlled Trials to assess how the treatment affects these various digestive symptoms.

The available research so far indicates that studies examining Gaviscon Forte reported a lessened severity and frequency of various indigestion symptoms. studies exploring Gaviscon Forte reported observations of symptom change, including for feelings like excessive fullness after eating or upper stomach discomfort. These observations were reported in studies investigating the treatment's use.

---

Use in Pregnancy-Related Heartburn

A specific area of research has focused on the use of this type of treatment for heartburn that occurs during pregnancy. The evidence from these dedicated studies suggests that treatments like Gaviscon Forte were studied for their effects on the frequent and often severe heartburn symptoms that occur as pregnancy progresses, with reports of symptom change.

The research exploring this use is often based on smaller or more observational studies compared to the large RCTs for general GERD. While the research included reports of changes in symptoms for pregnant individuals, there may be fewer studies directly comparing it to a wide range of other acid-reducing medicines specifically in this population. The long-term impact on the mother and child has been a major consideration in research, but most studies focus on symptom change within a typical course of pregnancy.

Key Studies & References

1. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies

Common questions about Gaviscon Forte (FAQ)

Q: What is Gaviscon Forte and how does it work?

Gaviscon Forte is an over-the-counter medication used to treat symptoms of gastroesophageal reflux (heartburn) and indigestion. It is a combination antacid and raft-forming agent.

It contains two active ingredients: sodium alginate and potassium bicarbonate.

• Sodium alginate reacts with stomach acid to form a protective 'raft' or physical barrier over the stomach contents. This physical barrier helps prevent stomach acid from flowing back up into the esophagus (reflux).
• Potassium bicarbonate acts as a source of carbon dioxide, which is essential for the rapid formation of the raft.

It works physically, providing relief by preventing reflux, often referred to as a barrier action.

Q: How quickly does Gaviscon Forte provide relief?

Gaviscon Forte is designed to provide fast relief from heartburn and indigestion symptoms. Because its mechanism of action is physical—forming a protective raft on top of the stomach contents—it begins working very soon after it is swallowed. Many users experience relief within minutes.

Q: Can Gaviscon Forte be taken on an empty stomach?

It is generally recommended to take Gaviscon Forte after meals and at bedtime (or when symptoms occur). Taking it after meals ensures there is stomach content (chyme) for the protective raft to form on, maximizing its effectiveness in preventing acid reflux.

Q: Does Gaviscon Forte contain aluminum?

No, Gaviscon Forte does not contain aluminum. Its active ingredients are primarily sodium alginate and potassium bicarbonate. Some other Gaviscon formulations may contain aluminum hydroxide or magnesium carbonate as antacids, but the Forte formulation relies on the alginate raft and bicarbonate for its primary action.

Q: What is the difference between Gaviscon Forte and regular Gaviscon?

The main difference between Gaviscon Forte and regular Gaviscon formulations is often the concentration of the active ingredients (sodium alginate and/or carbonates) and the overall formulation (e.g., liquid vs. tablets). Gaviscon Forte typically contains a higher concentration of sodium alginate, which enables it to form a more substantial or robust protective barrier (raft) on the stomach contents, potentially offering stronger or longer-lasting relief, especially for more intense symptoms of reflux.

Q: What are the common side effects of Gaviscon Forte?

Gaviscon Forte is generally well-tolerated, and side effects are uncommon. The most common side effects reported are related to the gastrointestinal tract and may include:

• Constipation
• Flatulence (gas)
• Bloating
• Nausea

In very rare cases, an allergic reaction (such as rash or difficulty breathing) may occur. If a severe reaction or persistent side effects are experienced, medical help should be sought immediately.

Q: Can Gaviscon Forte be used long-term?

Gaviscon Forte is intended for the short-term relief of symptoms like heartburn and indigestion. If symptoms are frequent, persistent, or severe, and require daily or long-term use of Gaviscon Forte, it is important to consult a healthcare professional. Persistent symptoms may indicate an underlying condition that requires proper diagnosis and different treatment.

Q: Is Gaviscon Forte gluten-free?

Yes, Gaviscon Forte is generally considered to be gluten-free. Most formulations do not contain gluten-containing ingredients. However, patients with celiac disease or severe gluten intolerance should always review the specific product label or contact the manufacturer to confirm the absence of cross-contamination or hidden ingredients.

Storage and Disposal of Gaviscon Forte

The storage of Gaviscon Forte Oral Suspension is strictly defined in regulatory labeling to maintain its pharmaceutical stability. The product must be stored at a temperature below 30°C. It is an explicit requirement that the medicine must not be frozen or refrigerated, as this can compromise the suspension's integrity. To protect the contents from environmental exposure, the container must be kept tightly closed during storage.

Once the bottle has been opened, the product has a limited in-use shelf-life and must be used within six months. As a mandatory safety measure for all medicines, the suspension must be stored out of the sight and reach of children.

Disposal of any expired or unused Gaviscon Forte should follow local regulatory requirements. The medicine should generally not be discarded by flushing it down the toilet or pouring it into wastewater systems.